Bis-imide granulatimide analogues as potent Checkpoint 1 kinase inhibitors

European Journal of Pharmacology

Volumn 554, Issue 2-3, 2007, Pages 106-112

  Hénon, Hélène ^a   Messaoudi, Samir ^a   Anizon, Fabrice ^a   Aboab, Bettina ^a   Kucharczyk, Nathalie ^b   Léonce, Stéphane ^b   Golsteyn, Roy M ^b   Pfeiffer, Bruno ^b   Prudhomme, Michelle ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Antitumor agent; Chk1 inhibitor; Granulatimide; Isogranulatimide

Indexed keywords

1,3,4,6 TETRAHYDRO 10 HYDROXY 7H DIPYRROLO[3,4 A:3,4 C]CARBAZOLE 1,3,4,6 TETRAONE; 1,3,4,6 TETRAHYDRO 7H DIPYRROLO[3,4 A:3,4 C]CARBAZOLE 1,3,4,6 TETRAONE; BENZENE; CHECKPOINT KINASE 1 INHIBITOR; ENZYME INHIBITOR; GRANULATIMIDE; INDOLE DERIVATIVE; ISOGRANULATIMIDE;

ANIMAL CELL; ARTICLE; ASCIDIACEA; CONTROLLED STUDY; DRUG ISOLATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALKALOIDS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HCT116 CELLS; HT29 CELLS; HUMANS; IMIDAZOLES; INDOLES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845336481     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.10.022     Document Type: Article

References (28)

1. Anderson H.J., Andersen R.J., and Roberge M. Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy. In: Meijer L., Jézéquel A., and Roberge M. (Eds). Progress in Cell Cycle Research vol. 5 (2003) 423-430
2. Berlinck R.G.S., Britton R., Piers E., Lim L., Roberge M., Moreira da Rocha R., and Andersen R.J. Granulatimide and isogranulatimide, aromatic alkaloids with G2 checkpoint inhibition activity isolated from the Brazilian ascidian Didemnum granulatum: structure elucidation and synthesis. J. Org. Chem. 63 (1998) 9850-9856
3. Chen P., Luo C., Deng Y., Ryan K., Register J., Margosiak S., Tempczyk-Russell A., Nguyen B., Myers P., Lundgren K., Kan C.C., and O'Connor P.M. The 1.7 ? crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell 100 (2000) 681-692
4. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
5. Gray N., Détivaud L., Doerig C., and Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6 (1999) 859
6. Hénon H., Messaoudi S., Hugon B., Anizon F., Pfeiffer B., and Prudhomme M. Synthesis of granulatimide bis-imide analogues. Tetrahedron 61 (2005) 5599-5614
7. Hénon H., Anizon F., Pfeiffer B., and Prudhomme M. Synthesis of dipyrrolo[3,4-a;3,4-c]carbazole-1,3,4,6-tetraones bearing a sugar moiety. Tetrahedron 62 (2006) 1116-1123
8. Hénon H., Anizon F., Kucharczyk N., Loynel A., Casara P., Pfeiffer B., and Prudhomme M. Expedited synthesis of substituted dipyrrolo[3,4-a;3,4-c]carbazole-1,3,4,6-tetraones structurally related to granulatimide. Synthesis (2006) 711-715
9. Hénon H., Anizon F., Golsteyn R.M., Léonce S., Hofmann R., Pfeiffer B., and Prudhomme M. Synthesis and biological evaluation of new dipyrrolo[3,4-a;3,4-c]carbazole-1,3,4,6-tetraones substituted with various saturated and unsaturated side chains via palladium catalysed cross-coupling reactions. Bioorg. Med. Chem. 14 (2006) 3825-3834
10. Hugon B., Pfeiffer B., Renard P., and Prudhomme M. Synthesis of isogranulatimide analogues possessing a pyrrole moiety instead of an imidazole heterocycle. Tetrahedron Lett. 44 (2003) 3927-3930
11. Hugon B., Pfeiffer B., Renard P., and Prudhomme M. Synthesis of granulatimide analogues bearing a maleimide instead of an imidazole heterocycle. Tetrahedron Lett. 44 (2003) 3935-3937
12. Hugon B., Pfeiffer B., Renard P., and Prudhomme M. Synthesis of isogranulatimides A and B analogues possessing a 7-azaindole unit instead of an indole moiety. Tetrahedron Lett. 44 (2003) 4607-4611
13. Jiang X., Zhao B., Britton R., Lim L.Y., Leong D., Sanghera J.S., Zhou B.B.S., Piers E., Andersen R.J., and Roberge M. Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide. Mol. Cancer Ther. 3 (2004) 1221-1227
14. Léonce S., Pérez V., Casabianca-Pignède M.R., Anstett M., Bisagni E., and Atassi G. In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest. New Drugs 14 (1996) 169-180
15. Luo Y., Rockow-Magnone S.K., Kroeger P.E., Frost L., Chen Z., Han E.K.H., Ng S.C., Simmer R.L., and Giranda V.L. Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism. Neoplasia 3 (2001) 411-419
16. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 33 (2000) 261-274
17. Piers E., Britton R., and Andersen R.J. Improved synthesis of isogranulatimide, a G2 checkpoint inhibitor. Syntheses of didemnimide C, isodidemnimide A, neodidemnimide A, 17-methylgranulatimide, and isogranulatimides A-C. J. Org. Chem. 65 (2000) 530-535
18. Prudhomme M. Combining DNA damaging agents and Chk1 inhibitors. Curr. Med. Chem.-Anti-Cancer Agents 4 (2004) 435-438
19. Prudhomme, M., 2006. Novel Chk1 inhibitors. Recent Patents on Anti-Cancer Drug Discovery, 1, 55-68.
20. Roberge M., Berlinck R.G.S., Xu L., Anderson H.J., Lim L.Y., Curman D., Stringer C.M., Friend S.H., Davies P., Vincent I., Haggarty S.J., Kelly M.T., Britton R., Piers E., and Anderson R.J. High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res. 58 (1998) 5701-5706
21. Suganuma M., Kawabe T., Hori H., Funabiki T., and Okamoto T. Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. Cancer Res. 59 (1999) 5887-5891
22. Tao Z.F., and Lin N.H. Chk1 inhibitors for novel cancer treatment. Anti-Cancer Agents Med. Chem. 6 (2006) 377-388
23. Walworth N., Davey S., and Beach D. Fission yeast chk1 protein kinase links the rad checkpoint pathway to cdc2. Nature 363 (1993) 368-371
24. Wang, L., Liu, X., Chen, R., 2003. Derivatives of isoindigo, indigo and indirubin and use in treating cancer, International patent WO03051900, CA 139:47135.
25. Yoshida T., Nishiyachi M., Nakashima N., Murase M., and Kotani E. New synthetic route to granulatimide and its structural analogues. Chem. Pharm. Bull. 50 (2002) 872-876
26. Yoshida T., Nishiyachi M., Nakashima N., Murase M., and Kotani E. Synthesis of granulatimide positional analogues. Chem. Pharm. Bull. 51 (2003) 209-214
27. Zhao B., Bower M.J., McDevitt P.J., Zhao H., Davis S.T., Johanson K.O., Green S.M., Concha N.O., and Zhou B.B.S. Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem. 277 (2002) 46609-46615
28. Zhou B.B.S., and Elledge S.L. The DNA damage response: putting checkpoints in perspective. Nature 408 (2000) 433-439